Metallothionein modulates the carcinogenicity of N-butyl-N-(4-hydroxybutyl)nitrosamine in mice

Carcinogenesis. 1999 Aug;20(8):1625-7. doi: 10.1093/carcin/20.8.1625.

Abstract

We examined the carcinogenicity of N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) in transgenic mice deficient in the metallothionein (MT) I and II genes and in control (129/Sv) mice. Both strains of mice were given BBN for 8 weeks with or without Zn treatment. All mice were killed at 12 weeks after the cessation of BBN administration. BBN induced bladder tumors in 75% of MT null mice and in 43% of 129/Sv mice. The average number of bladder tumors per mouse was significantly higher in MT null mice (1. 18 +/- 0.27) than in 129/Sv mice (0.43 +/- 0.20). Zn treatment suppressed the carcinogenicity of BBN in 129/Sv mice but not in MT null mice. Histopathological examination of the tumors revealed that the malignant potential of bladder tumors in 129/Sv mice was greater than that in MT null mice. These results indicate that MT is an important modulator of carcinogenicity of BBN in the bladder of mice.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Butylhydroxybutylnitrosamine / pharmacology
  • Butylhydroxybutylnitrosamine / toxicity*
  • Carcinogenicity Tests
  • Carcinogens / antagonists & inhibitors
  • Carcinogens / toxicity*
  • Carcinoma, Transitional Cell / chemically induced
  • Carcinoma, Transitional Cell / metabolism
  • Chlorides / pharmacology*
  • Metallothionein / deficiency
  • Metallothionein / drug effects*
  • Metallothionein / physiology
  • Mice
  • Mice, Transgenic
  • Urinary Bladder Neoplasms / chemically induced*
  • Urinary Bladder Neoplasms / metabolism
  • Urinary Bladder Neoplasms / pathology
  • Zinc Compounds / pharmacology*

Substances

  • Carcinogens
  • Chlorides
  • Zinc Compounds
  • Butylhydroxybutylnitrosamine
  • zinc chloride
  • Metallothionein